These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1019 related items for PubMed ID: 23351825

  • 1. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
    Ambrosy AP, Vaduganathan M, Mentz RJ, Greene SJ, Subačius H, Konstam MA, Maggioni AP, Swedberg K, Gheorghiade M.
    Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
    [Abstract] [Full Text] [Related]

  • 2. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial.
    Ambrosy AP, Pang PS, Khan S, Konstam MA, Fonarow GC, Traver B, Maggioni AP, Cook T, Swedberg K, Burnett JC, Grinfeld L, Udelson JE, Zannad F, Gheorghiade M, EVEREST Trial Investigators.
    Eur Heart J; 2013 Mar; 34(11):835-43. PubMed ID: 23293303
    [Abstract] [Full Text] [Related]

  • 3. Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
    Vaduganathan M, Ambrosy AP, Greene SJ, Mentz RJ, Subacius HP, Maggioni AP, Swedberg K, Nodari S, Zannad F, Konstam MA, Butler J, Gheorghiade M, EVEREST trial investigators.
    Circ Heart Fail; 2012 Nov; 5(6):750-8. PubMed ID: 23051949
    [Abstract] [Full Text] [Related]

  • 4. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
    Greene SJ, Vaduganathan M, Lupi L, Ambrosy AP, Mentz RJ, Konstam MA, Nodari S, Subacius HP, Fonarow GC, Bonow RO, Gheorghiade M, EVEREST Trial Investigators.
    Am J Cardiol; 2013 Feb 15; 111(4):574-81. PubMed ID: 23206923
    [Abstract] [Full Text] [Related]

  • 5. The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial.
    Greene SJ, Vaduganathan M, Wilcox JE, Harinstein ME, Maggioni AP, Subacius H, Zannad F, Konstam MA, Chioncel O, Yancy CW, Swedberg K, Butler J, Bonow RO, Gheorghiade M, EVEREST Trial Investigators.
    JACC Heart Fail; 2013 Dec 15; 1(6):488-96. PubMed ID: 24622000
    [Abstract] [Full Text] [Related]

  • 6. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).
    Shah AN, Mentz RJ, Gheorghiade M, Kwasny MJ, Fought AJ, Zannad F, Swedberg K, Maggioni AP, Konstam MA.
    Am J Cardiol; 2012 Dec 15; 110(12):1803-8. PubMed ID: 22999071
    [Abstract] [Full Text] [Related]

  • 7. Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial).
    Khan SS, Campia U, Chioncel O, Zannad F, Rossignol P, Maggioni AP, Swedberg K, Konstam MA, Senni M, Nodari S, Vaduganathan M, Subacius H, Butler J, Gheorghiade M, EVEREST Trial Investigators.
    Am J Cardiol; 2015 Mar 15; 115(6):790-6. PubMed ID: 25728846
    [Abstract] [Full Text] [Related]

  • 8. Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
    Greene SJ, Harinstein ME, Vaduganathan M, Subačius H, Konstam MA, Zannad F, Maggioni AP, Swedberg K, Butler J, Gheorghiade M, EVEREST Trial Investigators.
    Am J Cardiol; 2012 Dec 01; 110(11):1657-62. PubMed ID: 22917555
    [Abstract] [Full Text] [Related]

  • 9. Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial.
    Payvar S, Spertus JA, Miller AB, Casscells SW, Pang PS, Zannad F, Swedberg K, Maggioni AP, Reid KJ, Gheorghiade M, Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators.
    Eur J Heart Fail; 2013 Dec 01; 15(12):1382-9. PubMed ID: 23858000
    [Abstract] [Full Text] [Related]

  • 10. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial.
    Blair JE, Pang PS, Schrier RW, Metra M, Traver B, Cook T, Campia U, Ambrosy A, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Konstam MA, Gheorghiade M, EVEREST Investigators.
    Eur Heart J; 2011 Oct 01; 32(20):2563-72. PubMed ID: 21785107
    [Abstract] [Full Text] [Related]

  • 11. Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial.
    Girerd N, Pang PS, Swedberg K, Fought A, Kwasny MJ, Subacius H, Konstam MA, Maggioni A, Gheorghiade M, Zannad F, EVEREST investigators.
    Eur J Heart Fail; 2013 Nov 01; 15(11):1228-35. PubMed ID: 23787720
    [Abstract] [Full Text] [Related]

  • 12. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
    Anand IS, Rector TS, Kuskowski M, Thomas S, Holwerda NJ, Cohn JN.
    Circ Heart Fail; 2008 May 01; 1(1):34-42. PubMed ID: 19808268
    [Abstract] [Full Text] [Related]

  • 13. Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial.
    Mentz RJ, Chung MJ, Gheorghiade M, Pang PS, Kwasny MJ, Ambrosy AP, Vaduganathan M, O'Connor CM, Swedberg K, Zannad F, Konstam MA, Maggioni AP.
    Am Heart J; 2012 Dec 01; 164(6):884-92.e2. PubMed ID: 23194489
    [Abstract] [Full Text] [Related]

  • 14. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
    Lanfear DE, Sabbah HN, Goldsmith SR, Greene SJ, Ambrosy AP, Fought AJ, Kwasny MJ, Swedberg K, Yancy CW, Konstam MA, Maggioni AP, Zannad F, Gheorghiade M, EVEREST trial investigators.
    Circ Heart Fail; 2013 Jan 01; 6(1):47-52. PubMed ID: 23239836
    [Abstract] [Full Text] [Related]

  • 15. Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF.
    Verma AK, Sun JL, Hernandez A, Teerlink JR, Schulte PJ, Ezekowitz J, Voors A, Starling R, Armstrong P, O'Conner CM, Mentz RJ.
    Clin Cardiol; 2018 Jul 01; 41(7):945-952. PubMed ID: 29781109
    [Abstract] [Full Text] [Related]

  • 16. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial.
    Ambrosy AP, Vaduganathan M, Huffman MD, Khan S, Kwasny MJ, Fought AJ, Maggioni AP, Swedberg K, Konstam MA, Zannad F, Gheorghiade M, EVEREST trial investigators.
    Eur J Heart Fail; 2012 Mar 01; 14(3):302-11. PubMed ID: 22357577
    [Abstract] [Full Text] [Related]

  • 17. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, McMurray JJ, Zile MR, Komajda M, Massie BM, Carson PE.
    Circ Heart Fail; 2011 Sep 01; 4(5):569-77. PubMed ID: 21715583
    [Abstract] [Full Text] [Related]

  • 18. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
    Greene SJ, Gheorghiade M, Vaduganathan M, Ambrosy AP, Mentz RJ, Subacius H, Maggioni AP, Nodari S, Konstam MA, Butler J, Filippatos G, EVEREST Trial investigators.
    Eur J Heart Fail; 2013 Dec 01; 15(12):1401-11. PubMed ID: 23845795
    [Abstract] [Full Text] [Related]

  • 19. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial.
    Montero-Perez-Barquero M, Flather M, Roughton M, Coats A, Böhm M, Van Veldhuisen DJ, Babalis D, Solal AC, Manzano L.
    Eur J Heart Fail; 2014 Sep 01; 16(9):1009-15. PubMed ID: 25044535
    [Abstract] [Full Text] [Related]

  • 20. Association of blood pressure and its evolving changes with the survival of patients with heart failure.
    Grigorian-Shamagian L, Gonzalez-JuAnatey JR, Vazquez R, Cinca J, Bayes-Genis A, Pascual D, Fernandez-Palomeque C, Bardaji A, Almendral J, Nieto V, Macaya C, Jimenez RP, de Luna AB, Muerte Subita En La Insuficiencia Cardiaca (MUSIC) Group.
    J Card Fail; 2008 Sep 01; 14(7):561-8. PubMed ID: 18722321
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.